A recent study in mice published in Nature Medicine may have a significant effect on the future of human cancer vaccine research. Author, Willem Overwijk, explains that when mice were injected with a melanoma vaccine formulated with IFA, a compound designed to keep the vaccine in the body longer, their T-cells attacked the vaccine deposit under the skin rather than the tumor. Mice injected with an aqueous vaccine, however, had relocation of T-cells toward the tumor itself with a greater antitumor response. How has changing pharmaceutical formulations improved therapy outcomes for other drugs?
For more information on this topic, see NPR
Photo courtesy of [piyaphantawong/freedigitalphotos.net]